|Application ||WB, E|
|Other Accession||O35547, Q9QUJ7, NP_075266.1, NP_004449.1|
|Calculated MW||79188 Da|
|Antigen Region||28-56 aa|
|Other Names||Long-chain-fatty-acid--CoA ligase 4, Long-chain acyl-CoA synthetase 4, LACS 4, ACSL4, ACS4, FACL4, LACS4|
|Target/Specificity||This ACSL4 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 28-56 amino acids from the N-terminal region of human ACSL4.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||ACSL4 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||ACS4, FACL4, LACS4|
|Function||Activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially uses arachidonate and eicosapentaenoate as substrates.|
|Cellular Location||Mitochondrion outer membrane; Single-pass type III membrane protein. Peroxisome membrane; Single-pass type III membrane protein. Microsome membrane; Single-pass type III membrane protein. Endoplasmic reticulum membrane; Single-pass type III membrane protein|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The protein encoded by this gene is an isozyme of the long-chain fatty-acid-coenzyme A ligase family. Although differing in substrate specificity, subcellular localization, and tissue distribution, all isozymes of this family convert free long-chain fatty acids into fatty acyl-CoA esters, and thereby play a key role in lipid biosynthesis and fatty acid degradation. This isozyme preferentially utilizes arachidonate as substrate. The absence of this enzyme may contribute to the mental retardation or Alport syndrome. Alternative splicing of this gene generates 2 transcript variants.
Bosker, F.J., et al. Mol. Psychiatry (2010) In press :
Zhang, Y., et al. Hum. Mol. Genet. 18(20):3894-3905(2009)
Zeman, M., et al. Tohoku J. Exp. Med. 217(4):287-293(2009)
An, C., et al. Neurosci. Lett. 441(2):197-200(2008)
Hu, C., et al. Cancer Biol. Ther. 7(1):131-134(2008)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.